{"nctId":"NCT05033080","briefTitle":"A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Heterozygous for F508del and a Minimal Function Mutation (F/MF)","startDateStruct":{"date":"2021-09-14","type":"ACTUAL"},"conditions":["Cystic Fibrosis"],"count":435,"armGroups":[{"label":"ELX/TEZ/IVA","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: ELX/TEZ/IVA","Drug: IVA","Drug: Placebo (matched to VX-121/TEZ/D-IVA)"]},{"label":"VX-121/TEZ/D-IVA","type":"EXPERIMENTAL","interventionNames":["Drug: VX-121/TEZ/D-IVA","Drug: Placebo (matched to ELX/TEZ/IVA)","Drug: Placebo (matched to IVA)"]}],"interventions":[{"name":"VX-121/TEZ/D-IVA","otherNames":["VX-121/VX-661/CTP-656","VX-121/VX-661/VX-561","VX-121/tezacaftor/deutivacaftor"]},{"name":"ELX/TEZ/IVA","otherNames":["VX-445/VX-661/VX-770","elexacaftor/tezacaftor/ivacaftor"]},{"name":"IVA","otherNames":["VX-770","ivacaftor"]},{"name":"Placebo (matched to VX-121/TEZ/D-IVA)","otherNames":[]},{"name":"Placebo (matched to ELX/TEZ/IVA)","otherNames":[]},{"name":"Placebo (matched to IVA)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n* Heterozygous for F508del and a minimal function mutation (F/MF genotype)\n* Forced expiratory volume in 1 second (FEV1) value \\>=40% and \\<=90% of predicted mean for age, sex, and height for participants currently receiving ELX/TEZ/IVA therapy; FEV1 \\>=40% and \\<=80% for participants not currently receiving ELX/TEZ/IVA\n\nKey Exclusion Criteria:\n\n* History of solid organ or hematological transplantation\n* Hepatic cirrhosis with portal hypertension, moderate hepatic impairment (Child Pugh Score 7 to 9), or severe hepatic impairment (Child Pugh Score 10 to 15)\n* Lung infection with organisms associated with a more rapid decline in pulmonary status\n* Pregnant or breast-feeding females\n\nOther protocol defined Inclusion/Exclusion criteria may apply","healthyVolunteers":false,"sex":"ALL","minimumAge":"12 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)","description":"FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":null},{"groupId":"OG001","value":"0.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Absolute Change in Sweat Chloride (SwCl)","description":"Sweat samples were collected using an approved collection device.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","spread":null},{"groupId":"OG001","value":"-7.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With SwCl <60 mmol/L (Pooled With Data From Study VX20-121-103)","description":"Sweat samples were collected using an approved collection device.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"76.6","spread":null},{"groupId":"OG001","value":"85.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With SwCl <30 mmol/L (Pooled With Data From Study VX20-121-103)","description":"Sweat samples were collected using an approved collection device.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22.5","spread":null},{"groupId":"OG001","value":"30.5","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":41,"n":202},"commonTop":["Infective pulmonary exacerbation of cystic fibrosis","COVID-19","Cough","Nasopharyngitis","Headache"]}}}